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Abstract: The discovery of markers to lymphatic endothelial cells and the development of novel antibodies to
these markers have brought increasing attention to the lymphatics and progress in the understanding of lym-
phangiogenesis and cancer metastasis. In this study, we investigate the presence of lymphatic vessel invasion
(LVI) detected by D2-40 immunohistochemical staining in resected esophageal cancer and correlated with
clinicopathologic data and patient survival. Sixty nine patients, who had a primary resection of esophageal
cancer, were analyzed by univariate and multivariate logistic regression, and univariate and multivariate sur-
vival analysis. The total rate of LVI was 72% (50/69). Positive LVI was significantly correlated with lymph node
metastasis (p < 0.001), tumor size (p < 0.001), histological grading (p = 0.017), tumor depth (p = 0.001), and
stage (p < 0.001). Multivariate logistic analysis identified LVI (p = 0.036) as a predictor of regional lymph
node metastasis. On univariate survival analysis, patients with LVI had a significantly shorter disease-free
survival, cancer-specific survival and overall survival. Multivariate analysis proved that LVI diagnosed by D2-40
is an independent prognostic factor of both disease-free survival (p = 0.04) and overall survival (p = 0.032) in
resected esophageal cancer. These results show that LVI assessment identifies patients at high risk for regio-
nal lymph node metastasis and that LVI is an independent prognostic factor in patients with esophageal cancer.
(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 90–97)
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ageal cancer. More than 65% of patients with localized
esophageal cancers and negative resection margin have
a positive lymph node at the time of surgery [1]. How-
ever, despite complete tumor resection and extensive
lymphadenectomy, systemic and local recurrence is com-
mon [2] and the five-year survival rate is 15–39% [3].
The discovery over the last decade of markers of
lymphatic endothelial cells like podoplanin (D2-40)
[4], LYVE-1 [5] and Prox 1 [6], and the development
of novel antibodies to these markers, have generated
Introduction
The presence of lymph node metastasis is known to be
the most important prognostic factor in resectable esoph-
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increasing attention on lymphatics and progress in
the understanding of lymphangiogenesis and cancer
metastasis [7–9]. These markers enable the identifi-
cation of lymphatic vessels immunohistochemically.
Lymphatic vessel invasion (LVI) is known to be an
independent prognostic factor in patients with gastric and
colorectal cancer [10, 11]. It is also a predictor of lymph
node metastasis and indicates a poor prognosis, even in
node-negative patients with cervical and breast cancer
[12, 13]. Some studies have reported that LVI is one of
the histological risk factors for nodal metastasis of esop-
hageal cancer [14, 15]. The standard method of assessing
LVI is light microscopic examination of hematoxylin and
eosin (HE) stained sections. However, it is difficult to
detect LVI with conventional HE staining. Controver-
sies over the detection of LVI arise mainly from the diffi-
culty in visualizing the lymphatic vessel wall. According
to Alexander-Sefre et al. [16] accurate detection of LVI
has some limitations. First, tumor cells that completely
fill out the lymphatic channels make it difficult to diffe-
rentiate between LVI and stromal invasion. Second, the
artifactual spaces caused by tissue retraction due to fixa-
tion complicate the identification of true LVI.
The recently developed monoclonal antibody, D2-40,
recognizes a mucin-like transmembrane glycoprotein,
podoplanin, which is expressed in lymphatic endothe-
lial cells and enables the identification of lymphatic ves-
sels in paraffin section [17, 18]. It has been shown that
D2-40 is the most sensitive and specific antibody for the
detection of lymphatic endothelium in different malig-
nancies like gastric [19], colorectal [20], vulvar [21],
breast [22] and endometrial cancer [23].
In this study, we investigated the presence of LVI
detected by D2-40 immunohistochemical staining in
resected esophageal cancer and correlated with clini-
copathologic data and patient survival.
Material and methods
Patients and tissues
Tumor specimens were obtained from 69 patients with
primary esophageal cancer who underwent an esopha-
gectomy at the Department of Thoracic Surgery,
Medical University of Bialystok. The primary goal of
the surgical approach was a complete resection of the
primary tumor and its lymphatic drainage. None of
the patients had received preoperational chemothe-
rapy or radiotherapy treatment. The study popula-
tion consisted of 56 men (82%) and 13 women (18%).
The average age at the time of diagnosis was 64.2
years (range 44 to 77 years). The clinical features are
summarized in Table 1. None of the 69 patients died
within 30 days of the operation or during their hospi-
tal stay. Thirty patients received chemotherapy, ra-
diotherapy, or both, post-operatively. All patients have
been followed up regularly at our institution with rou-
tine physical and laboratory examination after dis-
charge. Follow-up examinations, such as computed
tomography, ultrasonography of the abdomen and
neck, and upper gastrointenstinal (GI) series were
carried out every three or six months. Endoscopic ex-
amination and PET-CT were performed when appro-
priate. The median follow-up period was 24 months
(range 3–101 months). Recurrence occurred in 35 ca-
ses. Nine patients had pulmonary metastasis, six patients
liver metastasis, five patients has pulmonary and liver
metastasis, 12 had mediastinal and neck lymph node
metastasis, and two cases relapsed in the esophagus
after operation. Thirty-one patients died of esophageal
cancer. Normal esophageal tissues were collected as
control specimens.
Analysis of protein expression
by immunohistochemistry (IHC)
The surgical specimens were fixed in 10% buffered
formalin solution for 24 h, embedded in paraffin and
handled in the Department of Pathology at the Medi-
cal University of Bialystok for further processing. The
tissue samples were obtained from the peripheral in-
vasion front of the tumor. Immunohistochemistry was
performed using the avidin-biotin-peroxidase com-
plex technique (ABC-technique). 4 mm-thick paraf-
fin-embedded slides were cut from each study block.
For antigen retrieval, the slides were heated in a mi-
crowave oven containing 0.01 mmol/L sodium citrate
(pH 6.0). The sections were treated with 0.3% H2O2
for 10 min at room temperature. The slides were in-
cubated for one hour at room temperature in a hu-
midity tray with primary antibodies — D2-40 (mouse
monoclonal antibody, 1:10, ABD-Serotec). The slides
were rinsed twice in 0.1 mmol/L PBS (pH ~7,4) for
5 min, and incubated for 30 min at room tempera-
ture with anti-goat biotinylated secondary antibody
(Vectastain ABC Kit, Vector), and anti-mouse bioti-
nylated secondary antibody (Peroxidase Detection
System, Novocastra) to identify the target. The sec-
tions were stained by 3’3-diaminobenzidine (DAB)
to visualize antigen-antibody complex. The nuclei
were then stained with Mayer hematoxylin. Positive
controls were made using tissue samples, as proposed
by the antibody manufacturer, which showed a high
expression of the proteins. Negative controls were
made with the same tissue without antibody.
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Definition of lymphatic vessel invasion (LVI)
Lymphatic vessel invasion (LVI) was evaluated by mi-
croscopic examination of the slides. The presence of
at least one tumor cell cluster in a podoplanin (D2-
-40)-positive vascular channel indicates LVI [19].
Statistical analysis
Distribution was analyzed by the Shapiro–Wilk test.
Categorical data was compared by the c2 or Fishers’
exact probability test. Logistic regression analysis was
used to identify univariable predictors of lymph node
metastasis. Variables that were significant in the
univariable analysis at p < 0.05 (and that made clini-
cal sense to include in a model to predict lymph node
involvement) were considered in a stepwise logistic
regression model. The results for the final multivaria-
ble model are summarized as the p value, odds ratio,
and 95% confidence interval for the odds ratio. Sur-
vival analysis was performed, including overall sur-
vival, disease-free survival and cancer-specific surviv-
al. Overall survival, disease-free survival and cancer-
specific survival were calculated from the date of sur-
gery to last contact for living patients, to the date of
the last follow-up for disease-free patients, and to the
date of esophageal–cancer-induced death, respective-
ly. The Kaplan–Meier method was used to estimate
the probability of survival as a function of time. The
differences in the survival of the subgroups of patients
were compared using the log-rank test. The prognos-
tic value of lymphatic vessel invasion was examined
in univariate and multivariate analysis with Cox’s pro-
portional hazard model. All p values were based on
two-tailed statistical analysis, and a p value of less
than 0.05 was considered significant. Statistical ana-
lyses were carried out using the Statistica 8.0 PL pro-
gram (StatSoft Inc., Tulsa, OK, USA) and the Graph
-Pad Prism 5.01 program (GraphPad Software, San
Diego, CA, USA).
In accordance with the Declaration of Helsinki, the
study protocol was approved by the local Ethics Com-
mittee (No R-1-002/188/2008) and written informed con-
sent was obtained from all participants before analysis.
Table 1. Characteristics of esophageal cancer patients
Parameters Number of patients
Esophageal cancer patients 69
Age < 64 years 22
≥ 64 years 47
Sex Female 13
Male 56
Location Upper 4
Midthoracic 25
Lower 40
Tumor size < 4 cm 33
≥ 4 cm 36
Histological type Squamous cell carcinoma 32
Adenocarcinoma 37
Histological grade Well-G1 7
Moderate -G2 29
Poor-G3 33
Tumor depth T1 6
T2 13
T3 45
T4 5
Stage I 6
IIA 19
IIB 5
III 39
Lymph node metastasis N0 22
N1 47
Residual tumor R0 57
R1 10
R2 2
G1 — well differentiated; G2 — moderately differentiated; G3 — poorly differentiated; T1 — tumor invades lamina propria or submucosa;
T2 — tumor invades muscularis propria; T3 — tumor invades adventitia; T4 — tumor invades adventitia; N0 — no regional lymph node metastases;
N1 — regional lymph node metastases; R0 — no residual tumor; R1 — microscopic residual tumor; R2 — macroscopic residual tumor
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Table 2. Clinical and histopathologic factors associated with lymphatic vessel invasion (LVI) detected by podoplanin
(D2-40)
Characteristics Number                                       LVI p
Negative Positive
Overall 69 19 50
Age
   < 64 22 8 14 0.385a
   ≥ 64 47 11 36
Sex
   Female 13 6 7 0.164a
   Male 56 13 43
Location
   Upper 4 1 3 0.291b
   Midthoracic 25 6 19
   Lower 40 12 28
Tumor size
   < 4 cm 33 16 17 < 0.001a
   ≥ 4 cm 36 3 33
Histological grade
   G1 7 5 2 0.017b
   G2 29 8 21
   G3 33 6 27
Stage
   I + II 30 16 14 < 0.001a
   III 39 3 36
T1 + T2 19 11 8 0.001a
T3 + T4 50 8 42
N0 22 15 7 < 0.001a
N1 47 4 43
R0 57 18 39 0.157a
R1 + R2 12 1 11
aFisher’s exact test; bc2 test; G1 — well differentiated; G2 — moderately differentiated; G3 — poorly differentiated; T1 — tumor invades
lamina propria or submucosa; T2 — tumor invades muscularis propria; T3 — tumor invades adventitia; T4 — tumor invades adventitia;
N0 — no regional lymph node metastases; N1 — regional lymph node metastases; R0 — no residual tumor; R1 — microscopic residual tumor;
R2 — macroscopic residual tumor
Figure 1. Lymphatic vessels with massive invasion (LVI)
detected by podoplanin (D2-40). The endothelial cells of
blood vessels did not stain with D2-40 (magnification × 400)
Figure 2. Cancer cell embolus that obliterated the lumen
of lymphatic vessels is clearly outlined by D2-40 positive
lymphatic vessels (magnification × 600)
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Results
In esophageal tumors, the lymphatic vessels identi-
fied with podoplanin were different in size and shape,
with a thin wall, without perivascular cells, and were
found in both tumor and peritumoral areas. None of
the podoplanin positive vessels were blood vessels.
Most lymphatic vessels with LVI were greatly en-
larged, sometimes with a tumor embolus (Figure 1).
In Figure 2, a tumor embolus that obliterated the lu-
men of the lymphatic vessels is clearly outlined by
D2-40 positive lymphatic vessels. The results of LVI
invasion and clinicopathological features are summa-
rized in Table 2. In this study, positive LVI with D2-
-40 immunostaining were detected in 72% (50/69) of
the cases of esophageal cancer patients. In LVI-posi-
tive patients, lymph node metastasis was observed
more frequently than in LVI-negative patients (43/
/50 vs. 4/19; p < 0.001). Of 47 patients with nodal
involvement, four (8.5%) were not stained with D2-
-40. Positive LVI was significantly correlated with tu-
mor size (p < 0.001), histological grade (p = 0.017),
tumor depth (p = 0.001), and stage (p < 0.001). No
significant difference was found between those with
positive and negative LVI in terms of age, sex, tumor
location, or residual tumor.
To investigate the risk factor of lymph node me-
tastasis, multivariate regression analyses were conduc-
ted to include tumor size, histological grade, depth of
invasion, residual tumor and lymphatic vessel invasion.
Logistic regression analysis identified LVI (p = 0.036),
increasing depth of tumor invasion (p = 0.016) and
increasing tumor size (p = 0.004) as multivariable pre-
dictors of regional lymph node metastasis. Other fac-
tors did not predict lymph node metastasis (Table 3).
Table 3. Logistic regression analysis in relation to lymph node metastasis
Factors Univariate p Multivariate
Odds ratio 95% CI p
Tumor size < 0.001 1.631 0.934–4.834 0.004
Histological grade 0.050 0.675 0.313–1.453 0.306
Depth of invasion 0.001 1.431 1.131–6.334 0.016
Residual tumor 0.048 0.911 0.623–3.264 0.104
LVI < 0.001 2.139 1.224–8.867 0.036
CI — confidence interval; LVI — lymphatic vessel invasion
Figure 3. Kaplan–Meier analysis of disease-free survival
according to lymphatic vessel invasion (LVI) detected by
podoplanin (D2-40) in patients with esophageal cancer
Figure 4. Kaplan–Meier analysis of cancer-specific survival
according to lymphatic vessel invasion (LVI) detected by
podoplanin (D2-40) in patients with esophageal cancer
Figure 5. Kaplan–Meier analysis of overall survival
according to lymphatic vessel invasion (LVI) detected by
podoplanin (D2-40) in patients with esophageal cancer
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Table 4. Cox regression analysis of independent factors affecting disease-free survival, cancer-specific survival
and overall survival
Factors                Disease-free survival                  Cancer-specific survival               Overall survival
HR (95% CI) p HR (95% CI) P HR (95% CI) p
Tumor size 0.72 (0.311–1.691) 0.45 0.49 (0.193–1.268) 0.14 0.68 (0.271–1.740) 0.42
Histological grade 2.26 (1.200–4.285) 0.01 1.85 (0.940–3.641) 0.07 1.76 (0.903–3.433) 0.09
Tumor depth
T1 + 2 vs. T3 + 4 1.08 (0.303–3.900) 0.89 1.51 (0.357–6.463) 0.57 1.90 (0.475–7.647) 0.36
Tumor stage
I + II vs. III 0.34 (0.093–1.304) 0.11 0.20 (0.049–0.847) 0.02 0.18 (0.048–0.722) 0.015
Lymph node metastasis 16.78 (2.903–97.033) 0.002 21.37 (2.518–65.378) 0.001 12.83 (2.518–65.378) 0.002
Residual tumor 2.72 (1.064–6.990) 0.03 3.33 (1.228–9.028) 0.01 3.38 (1.289–8.875) 0.013
LVI 4.80 (1.044–22.069) 0.04 4.07 (0.648–25.684) 0.13 5.58 (1.031–9.517) 0.032
HR — hazard ratio; CI — confidence interval; LVI — lymphatic vessel invasion
On univariate survival analysis, LVI was associa-
ted with poor disease-free survival (Figure 3, p <
< 0.001), cancer-specific survival (Figure 4, p < 0.001)
and overall survival (Figure 5, p < 0.001). Multivaria-
te regression analysis indicated that LVI could be
an independent prognostic factor for both disease-
-free survival (p = 0.04) and overall survival (p =
= 0.032), but not cancer-specific survival. Moreover,
lymph node metastasis and residual tumor could serve
as independent predictors for all three survivals
(lymph node metastasis, p = 0.002, 0.002, 0.001; re-
sidual tumor, p = 0.03, 0.013, 0.01, respectively). The
TNM stage was the independent prognostic predic-
tor for both overall survival (p = 0.015) and cancer-
-specific survival (p = 0.02). The histological grade
could be an independent prognostic factor for dise-
ase-free survival (p = 0.01) (Table 4).
Discussion
Lymph node metastasis is a complex biological pro-
cess initialized by tumor cells, also involving spread
through the lymphatic vessels to the lymph node. Al-
though lymphatic vessel invasion is included in the
TNM system as a ‘L’ category, its mention in the histo-
pathology report is optional. LVI has been little stu-
died due to the difficulties associated with detecting
and characterizing lymphatic markers. The develop-
ment of selective immunohistochemical markers for
staining lymphatic endothelial cells enable a more pre-
cise study of the lymphatic channels and the molecu-
lar mechanisms involved in lymphangiogenesis [24].
In this study, we evaluated LVI using podoplanin,
a 38 kDa mucin-type transmembrane glycoprotein
which is recognized by the monoclonal antibody D2-
-40 as a lymphatic marker. We showed that D2-40
was positive in the endothelial cells of lymph vessels
and identified tumor cell clusters in lymph vessels,
whereas, D2-40 did not react with the endothelium
of blood vessels. The distinction between lymph ves-
sels and blood vessels in esophageal cancer has also
been demonstrated using D2-40 [25].
The standard method for assessing LVI is light mi-
croscopic examination of hematoxylin and eosin (HE)
stained section. We identified LVI using D2-40 in
72% (50/69) of the cases of resected esophageal can-
cer. In various studies, the total rate of positive LVI
ranged from 39.1% to 49.9%. This is lower than in
the current study, but von Rahden et al. [14] and
Brücher et al. [15] assessed tumor cells in lymphatic
channels on HE stained slides. Our results suggest
that LVI in esophageal cancers occurs in more pa-
tients than is generally assumed.
In the current study, lymph node metastasis was
observed in 86% of LVI-positive patients. Tomita et
al. [26] obtained similar results. Lymph node me-
tastasis was significantly (p < 0.001) related with
the tissue status of lymphatic invasion, which were
diagnosed by D2-40 immunohistochemistry. This
suggests that LVI is thought to precede or occur
coincidently with lymph node metastasis. However,
four (8.5%) patients who were negative for LVI on
D2-40 had lymph node metastasis. Brücher et al.
[15] showed that 75.8% of patients with LVI assessed
on HE stained slides had lymph node involvement.
The increase in sensitivity of detection of LVI is at-
tributed to the demarcation of lymphatic endothe-
lium that stains positively for D2-40 around the tu-
mor cells. Nevertheless, D2-40 could be useful in
distinguishing true lymphatic invasion from retrac-
tion artifact.
We also found that positive LVI significantly cor-
related with tumor size, histological grade, tumor
depth, and stage. Our analysis clearly shows that LVI
is associated with more advanced disease and histo-
logical grade. This reflects the aggressiveness of
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esophageal cancer and suggests that many patients
with locally advanced tumors may already have sys-
temic, not just local, tumor disease.
In this study, we have shown that LVI, detected
using immunostaining with monoclonal antibody D2-
-40, is a histological risk factor predictive of lymph
node metastasis in patients with resected esophageal
cancer. This is in accordance with studies investiga-
ting a risk factor predictive of nodal involvement in
colorectal, vulvar and esophageal cancer [11, 21, 26].
Our observations indicate that the main source of
lymph node metastasis may be delivered from the lym-
phatic invasion in esophageal cancer.
We also found that increasing depth of tumor in-
vasion and tumor size were also predictors of lymph
node metastases. Deeper invasion into the esophageal
wall increases exposure to the lymphatics and the
potential for longitudinal lymphatic extension and
lateral metastasis to regional lymph nodes. Similar
esophageal cancer data were reported by Rice et al.
[27]. Age, sex, location, histological grade, or residu-
al tumor were not predictive of regional lymph node
metastasis.
The prognostic value of LVI has been shown in
patients with solid tumors like breast cancer [28],
colorectal carcinoma [29] and gastric carcinoma [30,
31]. In the current study, on univariate survival anal-
ysis, patients with LVI had a significantly shorter dise-
ase-free survival, cancer-specific survival and overall
survival.
Although our analysis clearly shows that LVI is
associated with more advanced disease, LVI is also
present in many patients with early disease. Multi-
variate analysis proved that LVI diagnosed by D2-40
immunohistochemistry is an independent prognostic
factor of both disease-free survival and overall sur-
vival in resected esophageal cancer.
In summary, LVI assessment identifies those pa-
tients at particularly high risk for regional lymph node
metastasis. Univariate and multivariate analyses re-
vealed the presence of LVI as an independent prog-
nostic factor and LVI should be included with other
established factors used in staging and treatment de-
cision-making for patients with esophageal cancer.
Based on our results, we recommend the use of
D2-40 immunoreactions for the routine evaluation
of lymphatic invasion in esophageal cancer.
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